Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Rhupus is a complex syndrome that combines rheumatoid arthritis and lupus, making diagnosis challenging.

Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.

Methotrexate improved skin condition in 64% of patients with generalized granuloma annulare.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Roxithromycin, an antibiotic, can increase hair growth and might be used as a treatment for hair loss.

A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

The treatment was not recommended due to limited effectiveness and significant side effects.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Rhupus is a complex syndrome that is hard to diagnose due to unclear clinical criteria.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.